| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 207.9 | 205.6 |
| Gross profit | 146.5 | 148.5 |
| Profit before tax | -5.2 | -22.3 |
| Net income | -6.1 | -22.8 |
| EPS (diluted, $ a share) | $-0.15 | $-0.57 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +1.1% |
|---|---|
| Gross margin | 70.5% |
| Operating margin | 0.7% |
10-Q filed with the SEC, NASDAQ: OFIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Orthofix Medical Inc.: key numbers
- Share price
- $6.80Close, Nov 16
- Market cap
- $277M
- Shares outstanding
- 40.76MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Orthofix Medical Inc.
All →Orthofix Medical Insider Juniper Investment Company LLC Buys $5.11M of Stock
Juniper Investment Company LLC bought 689,803 shares of Orthofix Medical Inc. at $7.04 to $7.41 a share (average $7.40) in 2 transactions, worth $5.11M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 4,461,019 (+0.3%).
- Value
- $5.11M
- Shares
- 689,803
- Average price
- $7.40
- Holding change
- +0.3%
- Trade date
- Nov 9, 2026 to Nov 11, 2026
Orthofix Medical Earnings Call: Key Takeaways
Orthofix reported a challenging Q3 2026, missing internal expectations due to US Spine market softness and supplier delays, leading to a downward revision of full-year revenue and EBITDA guidance.
- Call
- Nov 9, 2026, 8:30 AM ET
Orthofix Medical Financial Results
Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 1% increase over the prior year, and a net loss of $6.1 million. The company revised its full-year 2026 revenue guidance downward to $825M-$830M to reflect weaker performance in its U.S. Spine business and ongoing efforts to improve commercial execution.
- Term
- Q3 2026
“Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance. In U.S. Spine, we are accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity by focusing resources on our highest-performing distributor partners, products and market opportunities.”
Massimo Calafiore, President and Chief Executive Officer